Laken Kuntz, NP
Gerontology · Monroeville, PANPI 1700426962
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.7%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 71.1% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $6,329, 9.7 times the $654 reported in 2021. Among gerontology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $48.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Regeneron Healthcare Solutions, Inc.$449
- Johnson & Johnson$359
- Gilead$332
- Ardelyx, Inc.$195
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$8,00056%
- Food & beverage$6,22543%
- Education$1391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 109 | $10,209 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $1,013 |
| Regeneron Healthcare Solutions, Inc. | 17 | $449 |
| Johnson & Johnson | 21 | $359 |
| Gilead | 16 | $332 |
| Ardelyx, Inc. | 6 | $195 |
| Bristol Myers Squibb | 12 | $194 |
| Merck | 7 | $163 |
| E.r. Squibb & Sons, L.L.C. | 1 | $161 |
| Ferring Pharmaceuticals Inc. | 7 | $147 |
| Novo Nordisk | 4 | $147 |
| Redhill Biopharma Inc. | 8 | $140 |
| Sanofi | 7 | $130 |
| Braintree Laboratories, Inc. | 7 | $120 |
| Amgen | 4 | $87 |
| Fresenius Kabi USA, LLC | 4 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Phathom Pharmaceuticals, Inc. | 3 | $61 |
| Daiichi Sankyo Inc. | 3 | $61 |
| Pfizer | 3 | $57 |
| Digestive Care, Inc. | 1 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Celltrion USA Inc. | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Sandoz | 1 | $16 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,363 in reported general payments places this provider in the 95th percentile of 383 gerontology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 29 | $193,426 |
| CreonLipase/Protease/Amylase | 28 | $77,567 |
| RinvoqUpadacitinib | 11 | $77,255 |
| Mesalamine ErMesalamine | 161 | $59,735 |
| Mesalamine | 59 | $48,145 |
| XifaxanRifaximin | 12 | $39,168 |
| Mesalamine DrMesalamine | 38 | $17,425 |
| Pantoprazole Sodium | 1,018 | $12,690 |
| CholestyramineCholestyramine (With Sugar) | 85 | $6,747 |
| Famotidine | 441 | $4,356 |
| Budesonide DrBudesonide | 37 | $3,850 |
| Colesevelam Hcl | 13 | $3,386 |
| Ursodiol | 15 | $2,932 |
| Dexlansoprazole DrDexlansoprazole | 17 | $2,668 |
| Balsalazide Disodium | 23 | $2,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Rinvoq | $10,209 | $154,82239 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $71 | $39,16812 claims |
| SandozLansoprazole | $16 | $74646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 383 gerontology providers in Pennsylvania.
Other gerontology in Monroeville
- Elizabeth ChristensenMonroeville$3K
- Susan ScanlandScranton$517K
- Michelle BalbiAllentown$257K
- Melissa CallahanEphrata$76K
- Maria BonanniPhiladelphia$36K
- Lisa DevaneyWest Chester$27K
- Lora DillingerWyomissing$21K
- Kelly ShearerPittsburgh$12K
- Alanna MillerPhiladelphia$9K
- Mary KelleyPhiladelphia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.